Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld P, Hajek R, Nagler A, Spencer A, BladГ© J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ

http://www.ncbi.nlm.nih.gov/pubmed/18300257